3 completed, 3 recruiting, 2 not yet recruiting, 2 unknown. 4 Not applicable, 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Recruiting 2, Completed 1, Unknown 1 |
| Phase 2 | 2 | Withdrawn 2 |
| Phase 3 | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Growth Hormone-Secreting Pituitary Adenoma: new trials by email Literature Review of Growth Hormone-Secreting Pituitary Adenoma trials Research Report on Growth Hormone-Secreting Pituitary Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| Ultrasound in Predicting Difficult Intubation in Acromegaly Patients observational study - Acromegaly Due to Pituitary Adenoma, Difficult Intubation | Not yet recruiting | Başakşehir Çam & Sakura City Hospital | 34 | 2025-12-25 | 2025-12-29 | |
| Effects of Pasireotide Lar Therapy on Bone Metabolism morphometric spine radiography - Acromegaly Due to Pituitary Adenoma, Acromegaly | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 120 | 2025-09-08 | 2025-09-18 | |
| Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet Ketogenic diet, Diabetes Medication - Acromegaly Due to Pituitary Adenoma, Hyperglycemia | Not applicable | Recruiting | Leiden University Medical Center | 30 | 2025-07-29 | 2026-10-08 |
| KETOgenic Diet Therapy in Patients With ACROmegaly Ketogenic diet, Mediterranean diet - Acromegaly Due to Pituitary Adenoma, Ketogenic Diet | Not applicable | Recruiting | Erasmus Medical Center | 60 | 2023-06-01 | 2025-04-29 |
| Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor GIP-A, Placebo - Acromegaly Due to Pituitary Adenoma | Not applicable | Completed | University of Copenhagen | 25 | 2019-08-13 | 2023-11-29 |
| Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection - Acromegaly Due to Pituitary Adenoma | Phase 3 | Unknown | Samsung Medical Center | 90 | 2018-03-01 | 2018-03-01 |
| Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Educational Intervention - Pituitary Neoplasms, Prolactinoma | Not applicable | Unknown | Unity Health Toronto | 60 | 2014-02-01 | 2015-07-31 |
| Temozolomide in Treating Patients With Invasive Pituitary Tumors temozolomide, DNA methylation analysis, microarray analysis - Brain and Central Nervous System Tumors | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2009-12-01 | 2020-07-31 | |
| Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders Questionnaire - Brain and Central Nervous System Tumors, Metastatic Cancer | Completed | Case Comprehensive Cancer Center | 76 | 2005-05-01 | 2020-07-27 | |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer yttrium Y 90-edotreotide - Brain and Central Nervous System Tumors, Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 60 | 1998-01-01 | 2013-05-01 |
| Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Merkel Cell Carcinoma, Islet Cell Carcinoma | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 |
Pituitary Neoplasms (7) · Acromegaly (4) · Central Nervous System Neoplasms (3) · Astrocytoma (2) · Brain Neoplasms (2) · Carcinoma, Islet Cell (2) · Choroid Plexus Neoplasms (2) · Craniopharyngioma (2) · Ependymoma (2) · Glioblastoma (2) · Glioma, Subependymal (2) · Gliosarcoma (2) · Medulloblastoma (2) · Meningioma (2)
Brain Diseases (12) · Central Nervous System Diseases (12) · Endocrine Gland Neoplasms (12) · Endocrine System Diseases (12) · Hypothalamic Diseases (12) · Neoplasms by Histologic Type (12) · Neoplasms by Site (12) · Neoplasms, Glandular and Epithelial (12) · Nervous System Diseases (12) · Adenoma (11) · Neoplasms (11) · Pituitary Diseases (11) · Hypothalamic Neoplasms (7) · Nervous System Neoplasms (7) · Supratentorial Neoplasms (7)
Diet, Ketogenic (2) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Biological Therapy (1) · Complementary Therapies (1) · DNA Methylation (1) · Diet, Mediterranean (1) · Early Intervention, Educational (1) · Injections (1) · Microarray Analysis (1) · Observation (1) · Proton Therapy (1) · Radiosurgery (1) · Radiotherapy, Intensity-Modulated (1) · Solutions (1) · Surveys and Questionnaires (1)
Başakşehir Çam & Sakura City Hospital (1) · Burzynski Research Institute (1) · Case Comprehensive Cancer Center (1) · Erasmus Medical Center (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Jonsson Comprehensive Cancer Center (1) · Leiden University Medical Center (1) · Novartis Pharmaceuticals (1) · Samsung Medical Center (1) · Unity Health Toronto (1) · University College, London (1) · University of Copenhagen (1)
United States (3) · Netherlands (2) · Canada (1) · Denmark (1) · Italy (1) · South Korea (1) · Turkey (Türkiye) (1)
Anthony Heaney, MD (1) · John Suh, MD (1) · Larry K. Kvols, MD (1) · Mette H Jensen, MSc (1) · Michael Cusimano, MD, PhD (1) · Michael Kosmin (1) · Sabrina Chiloiro (1) · Stanislaw R. Burzynski, MD, PhD (1)